Read This Before Buying AMC stock

AMC reported Q3 2025 revenue of $1.3 billion (down 3.7% YoY), adjusted EBITDA of $122.2 million (down 24.4%), and a net loss of $298.2 million versus $20.7 million a year ago, with a large portion of the loss attributable to a one‑time refinancing non‑cash charge; free cash flow was negative $81.1 million and cash fell to $365.8 million from about $632.3 million earlier in the year. With roughly $4 billion of debt and limited excess cash even under a stronger Q4 box office, AMC has been funding losses via equity issuance and faces a Dec. 10 shareholder vote to double authorized shares to 1.1 billion, a move that would enable significant further dilution. The combination of persistent cash burn, heavy leverage and potential share dilution has driven the post‑earnings selloff, leading the article to advise avoiding AMC and to consider alternative theater exposure such as Cinemark.

Analysis

AMC reported Q3 2025 revenue of $1.3 billion, down 3.7% year‑over‑year, adjusted EBITDA of $122.2 million, down 24.4%, and a net loss of $298.2 million versus $20.7 million a year ago; net loss per share widened to ($0.58) from ($0.06). Management attributed part of the loss to a one‑time refinancing non‑cash charge, but negative free cash flow of $81.1 million and ongoing cash burn are concrete operating concerns.

The company’s cash balance fell from roughly $632.3 million earlier in the year to $365.8 million, while outstanding debt stands near $4 billion. Management has proposed doubling authorized shares from 550 million to 1.1 billion (Dec. 10 vote); even a targeted equity sale to restore cash to end‑2024 levels would imply issuance of over 100 million shares, and a scenario with Q4 adjusted EBITDA of ~$190 million would likely only cover interest and capex with little left to pay down principal.

Investor sentiment has turned sharply negative since the Nov. 5 earnings release as the dilution spiral and leverage profile create material downside risk; the article concludes the most prudent near‑term stance is to avoid initiating new positions and points to Cinemark as an alternative for theatre recovery exposure.

Key Decisions for Investors

• Avoid initiating or adding to long positions in AMC until there is clarity on the Dec. 10 shareholder vote and any specific equity issuance plans
• If already long, reduce exposure or implement hedges given the high likelihood of material dilution (>100 million shares) or increased leverage
• Monitor three key indicators closely: the vote outcome, any announced share issuance size/timing, and Q4 adjusted EBITDA and cash balance updates; treat failure to secure equity funding as a heightened solvency risk
• Consider reallocating theatre recovery exposure to peers with cleaner balance sheets such as Cinemark (CNK) rather than taking balance‑sheet risk with AMC